Mostrando resultados 1 - 7 de 7.

Resultados de la búsqueda

MONOCLONAL ANTIBODIES AGAINST SFRP1 FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE
CSIC and ISCIII have developed methods for the diagnosis and treatment of Alzheimer´s disease (AD) based on therapeutic monoclonal antibodies capable…
CONTROL DE ENFERMEDADES NEURODEGENERATIVAS CON DERIVADOS DE BENZOTIAZOL-BENZAMIDA
El CSIC ha desarrollado un grupo de compuestos heterocíclicos derivados de un núcleo estructural privilegiado con capacidad de inhibir la enzima…
COMPUESTOS REGULADORES DE LA TRANSMISIÓN SINÁPTICA PARA EL TRATAMIENTO DE ENFERMEDADES NEUROLÓGICAS
El CSIC y el Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) han desarrollado un grupo de compuestos que tienen la capacidad de regular…
CONTROL OF NEURODEGENERATIVE DISEASES WITH BENZOTHIAZOLE-BENZAMIDE DERIVATIVES
CSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This…
PURINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CSIC has synthesized several substituted purine derivatives that are capable of inhibiting the activity of the CDC7 kinase. This inhibitory activity…
PURINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CSIC has synthesized several substituted purine derivatives that are capable of inhibiting the activity of the CDC7 kinase. This inhibitory activity…
REGULATORY COMPOUNDS OF SYNAPTIC TRANSMISSION FOR THE TREATMENT OF NEUROLOGICAL DISEASES
The CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate…